Status:
TERMINATED
Activity and Balanced Eating to Reduce Comorbidities and Symptoms of MS
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Multiple sclerosis (MS) is the leading cause of irreversible neurological disability among young women and the second leading cause of disability among young men in the U.S. Cardiometabolic risk facto...
Eligibility Criteria
Inclusion
- Relapsing-Remitting MS
- On disease modifying treatment for 6 months
- No relapse within the previous 30 days
- BMI 25-55 kg/m2
- Self-identify as not currently meeting recommendations for healthy diet and physical activity
- Ambulatory with or without assistance
- Reliable access to the internet via computer or smartphone
- Responsible for their personal food preparation or have input into the food prepared for them
- Score indicating low cognitive functioning on the Telephone Interview for Cognitive Status assessment
Exclusion
- Physician does not approve participation
- Use of the following diabetes medications: Acetohexamide, Chlorpropamide (Diabinese), Tolbutamide (Orinase, Tol-Tab), Tolazamide (Tolinase), Glipizide (Glucotrol, Glucotrol XL, Metaglip), Glyburide (Micronase, DiaBeta, Glynase, Glucovance), Glimepiride (Amaryl), Humalog or lispro, Novolog or aspart, Apidra or glulisine, Regular (R) humulin or novolin, Velosulin (for use in the insulin pump), NPH (N), Lente (L), Ultralente (U), Lantus, Levemir or detemir, Humulin 70/30, Novolin 70/30, Novolog 70/30, Humulin 50/50, or Humalog mix 75/25
- Already on a specific diet meant to improve health
- Heart attack, stroke, or heart bypass surgery less than 6 months ago
- Pulmonary disease, cardiovascular disease or renal failure less than 6 months ago
- Smoking
- Cancer, HIV or liver/kidney disease
- Inability to travel to Lakeshore for testing
Key Trial Info
Start Date :
February 26 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 19 2020
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT03808545
Start Date
February 26 2019
End Date
March 19 2020
Last Update
November 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lakeshore Foundation
Birmingham, Alabama, United States, 35209